Abstract

The Kroger Co. will report fiscal second-quarter results on September 11, 2026 Pre-MKt; current expectations point to revenue of 34.57 billion US dollars year over year growth of 1.38%, adjusted EPS around 1.06 with a 6.54% increase, and EBIT near 1.01 billion, with investors focused on identical sales, margin resilience, and pharmacy dynamics.

Market Forecast

Consensus indicates The Kroger Co. will post revenue of 34.57 billion US dollars, up 1.38% year over year, adjusted EPS of 1.06 up 6.54%, and EBIT of 1.01 billion US dollars down 0.40% year over year. Forecast margin details were not disclosed in the latest dataset, so margin expectations remain anchored to prior commentary and recent trends. Core sales excluding fuel appear set for incremental growth supported by merchandising, value-price actions, and mix management, while investors will watch for pharmacy gross profit pressure and cost inflation in logistics. The most promising near-term contributor remains the non-fuel supermarket business at 40.46 billion US dollars last quarter, with the largest scale and breadth, though year-over-year growth by segment was not disclosed.

Last Quarter Review

The prior quarter delivered 46.12 billion US dollars of revenue, with a 23.04% gross profit margin, GAAP net profit attributable to shareholders of 0.90 billion US dollars and a 1.96% net profit margin, and adjusted EPS of 1.58, up 6.04% year over year. A key financial highlight was a top-line beat versus internal and external tracking, with reported revenue exceeding recent consensus inputs by approximately 0.65 billion US dollars. Main business highlights showed the non-fuel supermarket segment generating 40.46 billion US dollars, fuel contributing 5.26 billion US dollars, and other operations contributing 395.00 million US dollars; total revenue grew 2.22% year over year, though segment-level growth rates were not provided.

Current Quarter Outlook

Core Supermarket Operations

The central driver this quarter remains day-to-day supermarket performance excluding fuel. Several forces are interacting: promotional intensity in categories where price elasticity remains elevated, localized deflation in select center-store staples offset by fresh and prepared-foods mix, and a continued effort to calibrate price investments to traffic and basket metrics. Execution around private-brand penetration, in-stock rates, and shrink management is likely to influence gross profit outcomes as much as ticket size trends, making operational discipline as important as macro conditions for near-term results. On balance, a modestly positive comparable-sales backdrop would support the forecast trajectory for revenue and EPS, yet the spread between identical sales and cost growth will determine how much of the EBIT line can be defended in the quarter. Pharmacy is a swing factor inside the core business. Reimbursement dynamics and generic-drug margin cadence can compress or expand quarterly profits even when prescription volumes are stable. Recent commentary from the sell side suggests persistent headwinds in pharmacy profitability, which means management’s ability to offset those pressures with front-end merchandising, private-brand mix, and cost containment will be watched closely. Any incremental headwind from product recalls or short-term health-related events could be transitory but may still affect quarterly comps and labor scheduling. The quarter’s guideposts therefore include not only identical-store sales ex fuel, but also gross margin mix, shrink efficiency, and the magnitude of cost inflation in labor and logistics. Fuel economics will be less of a headline driver than the supermarket aisles, but fuel prices and diesel costs still ripple into freight, supply chain expense, and customer behavior. Elevated diesel costs in particular can flow through the P&L in ways that require offsetting productivity elsewhere in the store. The interplay between transportation costs and shelf availability remains a practical determinant of gross-to-net conversion. The setup this quarter implies a careful balance: cost containment and mix should protect margins, but any deviation in identical sales or pharmacy could shift EBIT toward the lower end of intra-quarter expectations.

Digital, Fulfillment, and High-ROI Growth Initiatives

Digital and fulfillment initiatives are positioned to provide steady contribution to sales, basket size, and loyalty metrics. The newly introduced option for customers to receive groceries and eligible prescriptions in a single order fulfilled through the company’s websites and apps with delivery by Instacart aligns with reducing friction, consolidating trips, and growing average order value. This cross-vertical convenience can enhance retention and deepen engagement with pharmacy and front-end categories, supporting revenue quality even if headline traffic is uneven. The initiative spans nearly all banners, increasing the probability of scaled adoption and consistent service levels. Leadership additions underscore a renewed urgency around execution in digital channels. The appointment of a chief eCommerce officer with deep scaling experience suggests a focus on last-mile efficiency, substitution accuracy, and out-of-stock remediation. In practical terms, improving pick accuracy and fill rates while lowering last-mile unit costs can shift digital orders from break-even to accretive, particularly when aided by higher-margin private-brand penetration in online baskets. As more online customers adopt regular delivery and subscription services, the business may realize lower churn, more frequent orders, and a better fixed-cost absorption profile. Complementing the digital push is the company’s continued emphasis on private brand value. Independent pricing work this summer indicated competitive private-label pricing versus peers, a factor that tends to compress shelf-price dispersion and encourage switching from national brands. As private brands increase share, they support margin mix and reduce volatility from vendor pricing cycles. This dynamic is important in a quarter where pharmacy may be a drag and supply-chain costs remain sensitive to fuel. Taken together, digital convenience plus private-brand expansion offers a credible path to stabilize margins and reinforce the EPS forecast band even when EBIT is under mild year-over-year pressure.

Near-Term Stock Price Drivers

Investor attention is likely to center on identical sales ex fuel, gross margin resiliency, and pharmacy profitability, as these three variables drive how revenue translates into EBIT and EPS. Identical sales that land close to or slightly below Street expectations may still be consistent with the forecast EPS if gross margin mix and operating expense leverage compensate. Conversely, a softer identical-sales print coupled with pharmacy compression could place EPS at risk unless offset by strong productivity, shrink improvement, and private-brand mix. Management’s commentary on the cadence of price investments and the health of traffic and basket will help frame the rest of fiscal year guidance. Another key driver is the integration and timeline planning for the announced acquisition of Giant Eagle for 1.65 billion US dollars. While the transaction’s closing and synergy realization lie beyond a single quarter, the market will assess management’s assertions about margin stability, EPS accretion timing, and regional strategies. Analysts who reviewed the deal characterized it as aligned with a margin-stable approach and an EPS-accretive catalyst, with synergies expected in merchandising and supply chain. Investors will parse any updates on integration steps, capital allocation, and the sequencing of store and distribution center changes. The clarity of this roadmap can influence how the market discounts forward earnings, especially as the current quarter’s EBIT is forecast modestly lower year over year. Cost trends and one-off operational headlines may add volatility around the print. Reports this summer highlighted investments in store hours, training, and uniforms, which can elevate cost growth in the short term but are intended to improve service consistency and sales conversion. External factors, such as elevated diesel costs, can bleed into freight and last-mile costs, while isolated food safety recalls or health-related outbreaks can temporarily disrupt categories. These factors are not structural, but their timing relative to the fiscal quarter can tilt near-term margins. Given these moving parts, the stock’s reaction will likely be most sensitive to a combination of identical sales, gross margin details by category, and management’s precision on full-year guardrails.

Analyst Opinions

Bullish views form the majority among recent notes tracked since January 2026, with approximately five positive opinions versus four neutral or cautious ones. Goldman Sachs reaffirmed a Buy rating with a 72 US dollars price target, framing the Giant Eagle acquisition as a growth-strengthening step. Wolfe Research echoed a positive stance, flagging the 1.65 billion US dollars deal as margin-stable and EPS-accretive, supporting a constructive multi-quarter narrative. Telsey Advisory reiterated Buy with an 82 US dollars target, citing dependable profitability drivers in digital engagement, private-brand mix, and alternative profit initiatives. Bank of America Securities reiterated a Buy rating with an 85 US dollars target, emphasizing momentum from profitable e-commerce behaviors and the potential for “alternative profit” contributions to reinforce earnings quality. Evercore ISI maintained an Outperform rating and adjusted its target to 75 US dollars, indicating confidence in the strategy’s ability to support consistent EPS even if EBIT is flat to slightly down in isolated quarters. The dominant bullish case rests on three pillars that align with this quarter’s setup. First, the expected year-over-year revenue growth of 1.38% and adjusted EPS growth of 6.54% suggest operational levers are functioning, particularly mix and expense control, despite pharmacy-specific headwinds. Second, the digital and pharmacy fulfillment integration is a tangible upgrade to the customer experience that can lift order frequency and basket size, thereby improving gross-to-net conversion in online channels; this is a lever that analysts believe can compound over the next year. Third, the Giant Eagle acquisition adds a defined path for incremental EPS through synergy capture in procurement, merchandising, and logistics, while remaining consistent with a disciplined margin profile. Bulls argue that such a posture provides resilience in quarters where individual line items, like pharmacy, introduce noise, as broader execution and cost control offer multiple offset mechanisms. Several bullish notes also highlight that private-brand economics and structural cost efforts can underpin margins even if identical sales vary by a few tenths relative to consensus. Private brands tend to sustain higher gross margins than national brands and, when coupled with digital convenience, support both customer value and profitability. Analysts’ constructive stance emphasizes that this combination can produce stability in a low-growth environment, which in turn helps the company sustain or grow EPS in line with the quarter’s 1.06 expectation. Moreover, the leadership additions in store operations and eCommerce are seen as positive signals that near-term execution remains a central priority, with best practices from seasoned operators being imported and localized across banners. The majority camp acknowledges risk factors but sees them as manageable within current guidance frameworks. Pharmacy reimbursement dynamics and certain cost lines, such as diesel-linked transportation expenses, may limit EBIT expansion in the near term, which is consistent with the forecast showing a 0.40% year-over-year decline in EBIT. However, bulls point out that a combination of mix management, productivity improvements, and private-brand expansion can keep adjusted EPS growing this quarter and throughout the fiscal year. That view aligns with a disciplined approach: protect margins where possible, allocate price investments strategically, and deploy capital into accretive, operationally coherent growth—principally digital fulfillment enhancements and the pending Giant Eagle integration plan. This is why the prevailing institutional view remains constructive heading into the print, with price targets clustered in the low-to-mid 70s and one prominent target at 85 US dollars. In summary, the prevailing opinion anticipates a quarter that meets or modestly exceeds the EPS consensus, supported by disciplined cost control and mix, even if EBIT is fractionally lower year over year. The bullish camp sees the core supermarket engine, strengthened digital convenience, and an accretive M&A roadmap as adequate to sustain EPS growth, which is the key lens through which institutional investors are evaluating near-term performance. While quarterly noise around pharmacy and logistics may continue, the majority view is that these are manageable within the company’s control variables, and that execution against identified levers should be sufficient to keep the earnings trajectory intact for the remainder of the year.